Vertex director granted shares and stock options
Vertex Pharmaceuticals director Alan M. Garber received equity awards as compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Vertex Pharmaceuticals director Alan M. Garber received equity awards as compensation. He was granted 472 shares of Common Stock in the form of restricted stock units that vest, subject to limited exceptions, on the first anniversary of the grant date. He was also granted stock options for 1,433 shares of Common Stock at an exercise price of $424.45 per share, which are fully vested and expire on April 30, 2036. Following the stock grant, he directly holds 7,344 shares of Vertex Common Stock in addition to these options.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 1,433 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 472 | $0.00 | $0.00 |
Footnotes (2)
- F1. Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
- F2. Fully vested.
Key Figures
Key Terms
Restricted stock unit financial
Stock Option (Right to Buy) financial
Fully vested financial
exercise price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Alan M. Garber receive in this Vertex (VRTX) Form 4 filing?
What are the terms of Alan M. Garber’s new Vertex (VRTX) stock options?
When do Alan M. Garber’s Vertex (VRTX) restricted stock units vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.